Skip to main content

Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy

Completed · Phase 4 · NCT06604442

Conditions: Prostate Cancer

At a glance

Research payments reported, 2025
$1.4M
U.S. investigators named
9
Sites paid
9
Planned or actual enrollment
62

About the trial

Sponsor
Blue Earth Diagnostics (with Aixial Group)
Tested
flotufolastat (18F) (drug), piflufolastat (18F) (drug)
Dates
Started 2024-12-04; completion 2025-08-29
Results posted
Yes

Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men with Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy

From ClinicalTrials.gov, last updated 2026-07-13. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Blue Earth Diagnostics reported $1.4M in research payments for this study in 2025 (91 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.